George Parides, DO
Pulmonary Disease · Mesa, AZNPI 1851379879
Payments from drug & device makers
Across 1,451 payments — averaging $628.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$833K
- Mylan Specialty L.p.$71K
- Verona Pharma, Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$571
- Boehringer Ingelheim$494
- GSK$476
- plus $5K from 47 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$912,624 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Mesa
- Mukesh AhluwaliaMesa$25K
- Steven FarberMesa$22K
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Robert OrrPeoria$1.6M
- Sachin ChaudharyTucson$1.2M
- Mark GotfriedPhoenix$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.